Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong
Authors' conclusion
These findings suggest that both molnupiravir and nirmatrelvir-ritonavir oral antiviral medications were associated with a lower risk of all-cause mortality and hospitalization among patients with COVID-19 and type 2 diabetes. Further studies in specific populations, such as individuals in residential care homes and individuals with chronic kidney disease, are suggested.
Study context
- Population
- Nonhospitalized patients in Hong Kong with T2D and confirmed SARS-CoV-2 infection, February 26 to October 23, 2022 (Omicron wave)matched cohorts
- Participants
- 22,098 patients
- Exposure
- Molnupiravir or nirmatrelvir-ritonavir vs nonuse
- Molnupiravirn = 921
- Molnupiravir controlsn = 921reference
- Nirmatrelvir-ritonavirn = 793
- Nirmatrelvir-ritonavir controlsn = 793reference
- Outcome
- Composite of:
- All-cause mortality
- Hospitalization
Methodological detailspopulation-based, 1:1 propensity score matching
- Population-based
- 1:1 propensity score matching
Main finding
As reported in the abstract
All-cause mortality and/or hospitalization
Hazard ratio (95% CI)P value
Molnupiravirvs Molnupiravir controlsmedian follow-up 102 days (IQR, 56-225 days)
0.71(0.64–0.79)
P < 0.001Nirmatrelvir-ritonavirvs Nirmatrelvir-ritonavir controlsmedian follow-up 85 days (IQR, 56-216 days)
0.71(0.63–0.80)
P < 0.001Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | P value | |
|---|---|---|---|
| In-hospital disease progressionMolnupiravirvs Molnupiravir controls | 0.49 (0.35–0.69) | P < 0.001 | |
| In-hospital disease progressionNirmatrelvir-ritonavirvs Nirmatrelvir-ritonavir controls | 0.92 (0.59–1.44) | P = 0.73 | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong. JAMA Netw Open. Published 1 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →